NCT03626870

Brief Summary

To assess the effect of resistin on neutrophil migration and intracellular bacterial killing

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 3, 2018

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 13, 2018

Completed
19 days until next milestone

Study Start

First participant enrolled

September 1, 2018

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2019

Completed
Last Updated

December 10, 2024

Status Verified

March 1, 2023

Enrollment Period

1 year

First QC Date

August 3, 2018

Last Update Submit

December 5, 2024

Conditions

Inflammation

Outcome Measures

Primary Outcomes (1)

  • intracellular bacterial killing, assessed by number of colonies of bacterial growth following neutrophil exposure to bacteria and resistin

    6 months

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all healthy volunteer adults

You may qualify if:

  • age ≥ 18
  • gender: male or female

You may not qualify if:

  • Adults who are unable to provide informed consent themselves
  • History of chronic kidney disease as defined by estimated glomerular filtration rate (GFR) \<60 ml/min prior to cardiogenic shock
  • Patients with hematologic malignancies
  • Pregnant women
  • Patient/surrogate is not fluent in English
  • Long-term immunosuppressive therapy
  • Prisoner
  • Patients on pre-existing continuous reno-renal therapy (CRRT) or intermittent hemodialysis (IHD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Penn State Milton S Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

Location

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Anthony Bonavia, MD

    Penn State Milton S Hershey Med Ctr

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Department of Anesthesiology

Study Record Dates

First Submitted

August 3, 2018

First Posted

August 13, 2018

Study Start

September 1, 2018

Primary Completion

September 1, 2019

Study Completion

September 1, 2019

Last Updated

December 10, 2024

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)